SCHEMBL4580281

SCHEMBL4580281

Nc1ccc(-c2ccc(F)cc2)cc1NC(=O)c1ccc(N2CC[C@H](O)C2)cc1

nearest known ligand 0.58

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 16/20 0.58
HDAC3 O15379 13/20 0.56
KCNH2 Q12809 2/20 0.55
HDAC1 Q13547 9/20 0.52
HDAC8 Q9BY41 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4580287 1.00 HDAC2 (0.58) HDAC2HDAC3KCNH2HDAC1HDAC8
SCHEMBL4580886 0.92 HDAC2 (0.63) HDAC2HDAC3KCNH2HDAC1HDAC8
SCHEMBL4578489 0.91 HDAC1 (0.61) HDAC2HDAC3KCNH2HDAC1
SCHEMBL4581071 0.91 HDAC1 (0.61) HDAC2HDAC3KCNH2HDAC1
SCHEMBL4578500 0.91 HDAC1 (0.61) HDAC2HDAC3KCNH2HDAC1
SCHEMBL4579194 0.90 HDAC2 (0.58) HDAC2HDAC3KCNH2HDAC1HDAC8
SCHEMBL4579191 0.90 HDAC2 (0.58) HDAC2HDAC3KCNH2HDAC1HDAC8
SCHEMBL4579297 0.90 HDAC2 (0.58) HDAC2HDAC3KCNH2HDAC1HDAC8
SCHEMBL4581046 0.85 HDAC2 (0.53) HDAC2HDAC3KCNH2HDAC1HDAC8
SCHEMBL4579404 0.85 HDAC2 (0.53) HDAC2HDAC3KCNH2HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007720-B1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2013-12-25 EP claimed
US-8598168-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2013-12-03 US claimed
EP-2007720-B1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2013-12-25 EP disclosed
US-8598168-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2013-12-03 US disclosed
EP-2007720-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2008-12-31 EP disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
WO-2007118137-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132503-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 HDAC2 5/4885HDAC3 3/4885KCNH2 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.